BiotechTube

GO-203-2C + Bortezomib

Phase 1Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 15/100
15
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Multiple Myeloma

Conditions

Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma

Trial Timeline

— → Jan 1, 2022

NCT ID
NCT02658396

About GO-203-2C + Bortezomib

GO-203-2C + Bortezomib is a phase 1 stage product being developed by Genus for Multiple Myeloma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02658396. Target conditions include Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma.

What happened to similar drugs?

20 of 20 similar drugs in Multiple Myeloma were approved

Approved (20) Terminated (0) Active (0)
✅Mirabegron + PlaceboAstellas PharmaApproved
✅Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + PlaceboAstellas PharmaApproved
✅TeclistamabJohnson & JohnsonApproved
✅BortezomibJohnson & JohnsonApproved
✅DaratumumabJohnson & JohnsonApproved
✅Mavenclad®MerckApproved
✅Mavenclad®MerckApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02658396Phase 1Withdrawn

Competing Products

20 competing products in Multiple Myeloma

See all competitors
ProductCompanyStageHype Score
mRNA-1195ModernaPhase 2
0
NEX-20ANanexa ABPhase 1
23
mRNA-2736ModernaPhase 1
0
mRNA-2808ModernaPhase 2
0
Placebo + PirtobrutinibEli LillyPhase 2
27
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomideEli LillyPhase 1/2
32
agenT-797MiNK TherapeuticsPhase 1
19
Duloxetine Hydrochloride (HCI) + PlaceboEli LillyPhase 3
40
TemferonGenenta SciencePhase 1/2
14
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
47
CT-P53 + US-Ocrevus + EU-OcrevusCelltrionPhase 3
47
CS-0777 tablets + CS-0777 tablets + CS-0777 tabletsDaiichi SankyoPhase 1
29
ASP7487, Velcade, DexamethasoneAstellas PharmaPhase 1/2
24
PHE885NovartisPhase 2
27
Mirabegron + PlaceboAstellas PharmaApproved
43
Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + PlaceboAstellas PharmaApproved
43
Denileukin Diftitox (Ontak)EisaiPhase 1
21
PalonosetronEisaiPhase 2
35
BIW-8962Kyowa KirinPhase 1
21
KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor)Kyowa KirinPhase 2
35